Skip to content

Urea/Hydrocortisone Topical

    DEA Class; Rx

    Common Brand Names; Carmol HC, U-Cort

    • Corticosteroids, Topical

    Hydrocortisone: anti-inflammatory, antipruritic and vasoconstrictive actions; mechanism of anti-inflammatory activity of topical corticosteroids unclear

    Indicated for relief of inflammation and pruritic associated with corticosteroid-responsive dermatoses

    Extent determined by many factors including vehicle, integrity of epidermal barrier, use of occlusive dressings

    Hypersensitivity to any components of preparation

    Hepatic insufficiency

    • Burning
    • Itching
    • Irritation
    • Dryness
    • Folliculitis
    • Hypertrichosis
    • Acneiform eruptions
    • Hypopigmentation
    • Perioral dermatitis
    • Allergic contact dermatitis
    • Maceration of the skin
    • Secondary infection
    • Skin atrophy
    • Striae
    • Miliaria

    Prolonged use may result in fungal or bacterial infection

    Contains sodium metabisulfite, which may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people

    Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia and glucosuria

    Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use and the addition of occlusive dressings Evaluate susceptible patients periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests; If HPA axis suppression is noted, withdraw the drug, reduce frequency of application, or substitute less potent steroid

    Pregnancy Category: C

    Lactation: Systemic hydrocortisone is excreted in breast milk, use caution

    Adults

    Apply to affected area q6-12hr; discontinue therapy when control achieved

    If no improvement within 2 weeks, reassess diagnosis

    Pediatric

    Apply to affected area q6-12hr; discontinue therapy when control achieved

    If no improvement within 2 weeks, reassess diagnosis

    Urea/hydrocortisone topical

    topical cream

    • 10%/1%